Enavatuzumab (PDL192) is a Humanized IgG1 Monoclonal Antibody Targeting TWEAK
Antibody-dependent cytotoxicity (ADCC) is a cell-mediated immune defense mechanism. The effector cells of the immune system actively cleave target cells, and their membrane surface antigens are bound by specific antibodies. Besides, it is one of the mechanisms by which antibodies, as part of the humoral immune response, can limit...